Login to Your Account

Clinical Genomics expands liquid biopsy for colon cancer

By Tamra Sami
Staff Writer

Thursday, August 31, 2017

PERTH, Australia – Australian biotech company Clinical Genomics Pty Ltd. will be able to dramatically expand the U.S. footprint of its liquid biopsy diagnostic to detect recurrent colon cancer following a new pact with Qiagen NV for its Paxgene blood collection system.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription